Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer

Clinical Hemorheology and Microcirculation

Volumn 24, Issue 2, 2001, Pages 93-99

  Kaibara, Manabu ^a   Watanabe, Takaya ^a   Ooka, Fumiko ^a   Liang, Shan Guang ^a   Aisaka, Kohzo ^a   Okinaga, Shoichi ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLASMIN; PLASMINOGEN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BLOOD CLOTTING TIME; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMATOCRIT; HEMOSTASIS; HUMAN; OSCILLATION; PARTIAL THROMBOPLASTIN TIME; THROMBOCYTE COUNT; THROMBOEMBOLISM;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIPLASMIN; ANTITHROMBIN III; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD VISCOSITY; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; HEMATOCRIT; HEMOSTASIS; HUMANS; HYSTERECTOMY; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PEPTIDE HYDROLASES; PLASMIN; PLATELET COUNT; RISK; THROMBOPHILIA;

EID: 0034987002     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. I.F. Boyd, W. Pollard and J.B. Blaickley, Preoperative intramuscular progestogen in the treatment of endometrial carcinoma, J. Obstet. Gynecol. Brit. Com. 80 (1973), 360-363.
2. M. Kaibara and M. Date, A new rheological method to measure fluidity change of blood during coagulation: application to in vitro evaluation of anticoagulability of artificial materials, Biorheology 22 (1985), 197-208.
3. F. Perrersson, P. Kolstad, H. Ludwig and H. Ulfelder, eds., Annual Report on the results of treatment in gynecological cancer, Vol. 19, FIGO, Stockholm, 1985.
4. M.A. Quinn, M.C. Anderson, C.A.E. Coulter and W.P. Scoutter, in: Gynecology, 2nd ed, R.W. Shaw, W.P. Soutter and S.L. Stanton, eds, Churchill Livingstone, New York, 1997, pp. 585-603.
5. R.M. Kelly and W.H. Baker, Progestational agents in the treatment of carcinoma of the endometrium, New Engl. J. Med. 264 (1961), 216-222.
6. Report from the Ministry of Health and Welfare in Japan. Thromboembolic complications in patients with breast and endometrial cancer during treatment of high dose medroxyprogesterone acetate, lyakuhin Kenkyu, 1993, pp. 664-671 (in Japanese).
7. R. Rosso, F. Boccardo, L. Canobbio, M.A. Queirolo, D. Zarcone and F. Brena, Effects of high-dose medroxyprogesterone acetate on blood-clotting factors and platelet function, Proc. Int. Symp. MPA (1982), 151-157.
8. E.M. Gordon, S.R. Williams, B. Frenchek, C.A. Mazur and L. Speroff, Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII, J. Lab. Clin. Med. Ill (1988), 52-56.
9. M. Bonsignori, G. Rossi and F. Stürbe, Protective effect of high dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumor: a multicentric controlled clinical trial, Chemioterapta 5 (1986), 134-139.
10. J.A. Dormandy, Clinical significance of blood viscosity, Ann. R. Coll. Surg. Eng. 47 (1970), 211-228.